Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML — Stella
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(21 sites) United States
O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama Ochsner Clinic Foundation, New Orleans, Louisiana Clinical Research Alliance, Inc., Lake Success, New York New York - Presbyterian Hospital, New York, New York UNC School of Medicine, Division of Hematology, Chapel Hill, North Carolina Bon Secours St. Francis Cancer Center, Greenville, South Carolina Baylor Scott & White Health, Dallas, Texas MD Anderson, Houston, Texas China
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui Anhui Provincial Hospital, Hefei, Anhui Affiliated Cancer Hospital of Chongqing University, Chongqing, Chongqing Municipality Cancer prevention and treatment center of Sun Yat sen University, Guangzhou, Guangdong Guangdong Provincial People's Hospital, Guangzhou, Guangdong Affiliated Hospital of Hebei University, Baoding, Hebei Henan Cancer Hospital, Zhengzhou, Henan The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu The First Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi Shengjing Hospital Affiliated to China Medical University, Shenyang, Liaoning Linyi Cancer Hospital, Linyi, Shandong Blood disease hospital, Chinese Academy of Medical Science, Tianjin, Tianjin Municipality
Key details Phase
Early testing / Safety & dosing
Sponsor
Sellas Life Sciences Group
Enrollment target
~160 participants
Primary completion
December 2026
Age range
12 Years and older
Last updated March 2026
Interested in joining? The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang